{
    "clinical_study": {
        "@rank": "21739", 
        "arm_group": [
            {
                "arm_group_label": "MEDI4736 Q2W", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MEDI4736 Q3W", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MEDI4736 Dose Expansion", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with\n      a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics\n      in Japanese patients with advanced solid tumor."
        }, 
        "brief_title": "A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Japanese Patients With Advanced Solid Tumors", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Advanced solid tumors that is refractory to standard therapy and for which no\n             standard therapy exists. - Japanese men or women. - Eastern Cooperative Oncology\n             Group (ECOG) status of 0 or 1. - Adequate organ and marrow function. - Subjects must\n             have at least 1 measurable lesion. - Available archived tumor tissue sample. -\n             Willingness to provide consent for biopsy samples.\n\n        Exclusion Criteria:\n\n          -  Any prior Grade \u2265 3 irAE while receiving immunotherapy - Prior exposure to any\n             anti-PD-1 or anti-PD-L1 antibody - Active or prior documented autoimmune disease\n             within the past 2 years - History of primary immunodeficiency - Symptomatic or\n             untreated central nervous system (CNS) metastases requiring concurrent treatment -\n             Women who are pregnant or lactating - Uncontrolled intercurrent illness - Known\n             history of tuberculosis - Known to be human immunodeficiency virus (HIV) positive -\n             Hepatitis B or C infection - Other invasive malignancy within 5 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "118", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938612", 
            "org_study_id": "D4190C00002"
        }, 
        "intervention": {
            "arm_group_label": [
                "MEDI4736 Q2W", 
                "MEDI4736 Q3W", 
                "MEDI4736 Dose Expansion"
            ], 
            "description": "MEDI4736 will be administered by IV infusion.", 
            "intervention_name": "MEDI4736", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "MEDI4736", 
            "Advanced solid tumors", 
            "B7-H1", 
            "PD-L1"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chuo-ku", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matsuyama-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Japanese Patients With Advanced Solid Tumors", 
        "overall_contact": {
            "email": "ClinicalTrialTransparency@astrazeneca.com", 
            "last_name": "Roxanne Akhavain", 
            "phone": "301-398-0000"
        }, 
        "overall_official": {
            "affiliation": "MedImmune LLC", 
            "last_name": "James Vasselli, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Ministry of Health, Labor and Welfare", 
                "Japan: Pharmaceuticals and Medical Devices Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety profile will be assessed through number of participants experiencing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, and physical examinations.", 
            "measure": "Number of participants experiencing dose-limiting toxicities, adverse events (AEs), serious adverse events (SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "90 days after the last dose of MEDI4736"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938612"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "If data allow, noncompartmental PK parameter (AUC) will be estimated.", 
                "measure": "Area under the concentration time curve", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "The immunogenic potential of MEDI4736 will be assessed by summarizing the number percentage of subjects who develop detectable anti-drug antibodies (ADAs).", 
                "measure": "Percentage of subjects who develop detectable anti-drug antibodies (ADAs).", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months after the last dose of MEDI4736."
            }, 
            {
                "measure": "Objective response rate (ORR)", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drug until death or up to 2 years"
            }, 
            {
                "description": "maximum tolerated dose (MTD) or optimal biological dose (OBD) of MEDI4736, if possible", 
                "measure": "Maximum tolerated dose (MTD) or optimal biological dose (OBD)", 
                "safety_issue": "Yes", 
                "time_frame": "90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "If data allow, noncompartmental PK parameter (Cmax) will be estimated.", 
                "measure": "Maximum concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "If data allow, noncompartmental PK parameter (CL) will be estimated.", 
                "measure": "Clearance", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "If data allow, noncompartmental PK parameter (t\u00bd) will be estimated.", 
                "measure": "half-life after administration of MEDI4736", 
                "safety_issue": "No", 
                "time_frame": "Up to 90 days after the last dose of MEDI4736"
            }, 
            {
                "description": "The immunogenic potential of MEDI4736 will be assessed by summarizing the percentage of subjects who develop detectable anti-drug antibodies (ADAs).", 
                "measure": "percentage of subjects who develop detectable anti-drug antibodies (ADAs).", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months after the last dose of MEDI4736."
            }, 
            {
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drug until death or up to 2 years"
            }, 
            {
                "measure": "Duration of response (DR)", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drug until death or up to 2 years"
            }, 
            {
                "measure": "Progression-free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drug until death or up to 2 years"
            }, 
            {
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "From first dose of study drug until death or up to 2 years"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}